Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Results suggest that patients with v1 exhibited no significant difference from non-v1 in terms of OS and PFS, while v3 was associated with shorter OS in ALK-positive patients with non-small cell lung cancer.
Wang et al. 2022 Future Oncology 18: 385-402

The ALK gene is rearranged in 3–7% of Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m).
Blakely & Riess 2019 Expert Review of Anticancer Therapy 19: 1061-1075…

References (Sources)

Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC
Blakely & Riess 2019 Expert Review of Anticancer Therapy 19: 1061-1075
Review
Lorlatinib as a treatment for ALK-positive lung cancer
Baba & Goto 2022 Future Oncol. 18(24): 2745-2766
Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives
Ryser et al. 2019 Current Opinion in Oncology 31: 8-12

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m)

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat